For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 + GHRP-6 Stack vs CJC-1295 / Ipamorelin Stack

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 + GHRP-6 StackCJC-1295 / Ipamorelin Stack
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination
EvidenceResearch-stageFDA-approved
Dosing rangeCJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning)100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)
AdministrationSubcutaneous injectionSubcutaneous injection (both compounds), Administered together in the same injection
Key side effectsStrong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin)Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)
Cited sources2 references2 references

Key differences

  • Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while CJC-1295 / Ipamorelin Stack is fda-approved.
  • Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection.
  • Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); CJC-1295 / Ipamorelin Stack is once daily before sleep (or 2–3x daily for more aggressive protocols).

How each works

CJC-1295 + GHRP-6 Stack

The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

Read the full CJC-1295 + GHRP-6 Stack profileRead the full CJC-1295 / Ipamorelin Stack profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.